G47Δ-mAngio improved tumor lysis, anti-angiogenesis, survive rate, and decreased VEGF expression and BEV-induced invasion markers during BEV combination treatment in mice-bearing human glioblastoma.240 RAMBO, another angiostatin-armed oHSV, has a similar effect to G47Δ-mAngio,241 and also in subcutaneously implanted sarcoma tumors.242 Besides oHSV, Ads have been studied and reformed. The gene discussed is VEGFA; the disease is neoplasm.